TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hypoplastic left heart syndrome or related single, morphologic right ventricle anomaly~* Planned Norwood procedure~* Informed consent of parent(s) or legal guardian~Exclusion Criteria:~* Single, morphologic left ventricle anomaly~* Preoperative identification of anatomy rendering either an MBTS or an RV-to-PA shunt technically impossible~* Any major congenital abnormality (i.e., congenital diaphragmatic hernia, tracheoesophageal fistula) or acquired extra-cardiac disorder (e.g., meconium aspiration with need for high frequency ventilation, persistent renal failure requiring dialysis) that, in the opinion of the investigator, could independently affect the likelihood of the subject meeting the primary endpoint

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MBTS (Type: ACTIVE_COMPARATOR): Blalock-Taussig pulmonary artery shunt
- RVPAS (Type: ACTIVE_COMPARATOR): Right ventricular to pulmonary artery shunt

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18-65 years of age, inclusive, at time of informed consent.~* Must have moderate to severe active non-segmental vitiligo.~Exclusion Criteria:~* History of human immunodeficiency virus (HIV) or positive HIV serology at screening,~* Infected with hepatitis B or hepatitis C viruses.~* Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks
- Cohort 2 (Type: EXPERIMENTAL): Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
- Cohort 3 (Type: EXPERIMENTAL): Maintenance dose A given QD for 24 weeks
- Cohort 4 (Type: EXPERIMENTAL): Maintenance dose B given QD for 24 weeks
- Cohort 5 (Type: EXPERIMENTAL): Maintenance dose C given QD for 24 weeks
- Cohort 6 (Type: PLACEBO_COMPARATOR): Placebo given QD for 24 weeks
- Extension Cohort 1 (Type: EXPERIMENTAL): 4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks
- Extension Cohort 2 (Type: EXPERIMENTAL): Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy
- Extension Cohort 3 (Type: EXPERIMENTAL): Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
- Extension Cohort 4 (Type: EXPERIMENTAL): Maintenance dose A given QD for 24 weeks
- Extension Cohort 5 (Type: EXPERIMENTAL): Maintenance dose B given QD for 24 weeks
- Extension Cohort 6 (Type: NO_INTERVENTION): Observation period for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) and satisfy the approved therapeutic indication for DMF (per the local DMF product information).~* Must be naïve to DMF, Fumaderm®, and other compounded fumarates, and to MS therapies that are primarily prescribed second-line (e.g., natalizumab, fingolimod) and to alemtuzumab.~* Have a recent complete blood count (CBC) that does not preclude the subject's participation in the study, in the judgment of the Investigator.~Key Exclusion Criteria:~* Are unwilling or unable to comply with study requirements, or are deemed unsuitable for study participation as determined by the Investigator.~* Have major comorbid conditions that preclude participation in the study, as determined by the Investigator.~* Are pregnant, unless DMF is clearly needed and the potential benefit of DMF to the subjects justifies the potential risk to the fetus, in the judgment of the Investigator (in all countries except Austria). In Austria, pregnant subjects are excluded from participation in the study.~* Are women of childbearing potential and are not using appropriate contraception (per the local DMF product information) as determined by the Investigator.~* Women who are breastfeeding may be excluded (per the local DMF product information) at the discretion of the Investigator.~* Have previously received or are receiving treatment with MS therapies primarily used second-line (e.g., natalizumab, fingolimod) or alemtuzumab, or are currently receiving and planning to continue on other disease-modifying therapies for RRMS.~* Are hypersensitive to the active ingredient in the DMF drug product (i.e., DMF) or to any of the excipients listed in the local DMF product information.~* Current enrollment in any clinical trial except for the Biogen Idec DMF Pregnancy Exposure Registry or other studies that, according to the study Medical Director, do not conflict with this study (e.g., health economics studies or local registries).~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DMF (Type: EXPERIMENTAL): 120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent from parent(s) or legal guardian(s).~* Age:~Cohort I: 12 - 23 mo. Cohort II: 9 - 11 mo. Cohort III: 6 - 8 mo. Cohort IV: 3 - 5 mo. Cohort V: 0 - 2 mo.~* Confirmed laboratory diagnosis of influenza by viral culture or rapid influenza diagnostic test within 96 hours prior to study enrollment.~* Duration of influenza symptoms less than or equal to 96 hours.~Exclusion Criteria:~* Concomitant vomiting illness that would preclude ability to take drug.~* Immunocompromised subject (e.g., malignancy, congenital agammaglobulinemia, HIV).~* Documented renal impairment (e.g., polycystic renal disease, nephrectomy, renal transplantation, renal agenesis, dialysis requirement, renal failure, nephrotic syndrome at any time prior to enrollment, current receipt of diuretic therapy).~* Documented hepatic impairment (e.g., congenital hepatitis, biliary atresia, cholelithiasis).~* Gastrointestinal abnormality which might hinder absorption of an oral medication.~* Current receipt of inotropic drugs (e.g., epinephrine, norepinephrine, dopamine, dobutamine).~* History of seizures.~* Documented congenital malformations of the central nervous system defined at birth (e.g., hydranencephaly, prosencephaly, spina bifida).

- Gender: ALL
- Minimum Age: None
- Maximum Age: 23 Months
- Healthy Volunteers: f

Study Arms:
- oseltamivir (Tamiflu®) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Stage IV breast cancer~* Measurable disease~* Progressive disease~  * Increase in disease mass or less than partial response to therapy~ * At least one prior chemotherapy regimen for metastatic disease and progressed~    * Must have received prior therapy with a taxane and an anthracycline~* Estrogen/progesterone receptor-positive patients must have received and progressed on at least one hormonal agent in adjuvant or metastatic setting~* Her2-neu-expressing patients must have received and progressed on trastuzumab (Herceptin®) in adjuvant or metastatic setting~* Prior autologous stem cell transplantation allowed if less than complete response or disease progression in adjuvant or metastatic setting~* Consenting first-degree relative with at least 5 out of 6 HLA-antigen match (may include mismatch at the D locus)~* Hormone receptor status:~  * Estrogen receptor status known~ * Progesterone receptor status known~PATIENT CHARACTERISTICS:~Age:~* 18 to 70~Sex:~* Male or female~Menopausal status:~* Not specified~Performance status:~* Karnofsky 80-100%~Life expectancy:~* More than 6 months~Hematopoietic:~* Not specified~Hepatic:~* Bilirubin ≤ 2 mg/dL~* SGOT \< 4 times upper limit of normal~* Hepatitis B surface antigen negative~* Hepatitis C antibody negative~Renal:~* Creatinine ≤ 1.5 mg/dL~* Creatinine clearance ≥ 50 mL/min~Cardiovascular:~* Left ventricular ejection fraction \> 45%~Pulmonary:~* DLCO ≥ 50% of predicted~Other:~* HIV negative~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~* Recovered from prior stem cell transplantation~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* See Disease Characteristics~* No concurrent steroids~Radiotherapy:~* Not specified~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female ages 50 years or older~* Must have a recent hip fracture repair in the past 90 days~* Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture~Exclusion Criteria:~* Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sex and Obesity: Effects on Heart Failure Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Heart failure (HF) and a systolic ejection fraction \<45% per a recent echocardiogram report)~* Nonischemic HF New York Heart Association Class II-III~* Ambulatory~* Able to give informed consent~* On a stable medical regimen including the standard-of-care HF medications (i.e., a beta-blocker, ACE-inhibitor or angiotensin receptor blocker \[ARB\])~Exclusion criteria~* Participants who were pregnant or lactating~* Actively losing weight~* Nonsedentary (performing aerobic exercise \> 30 minutes x 3 times/week)~* Those who have more than Class I hypertension~* Those who require alterations in beta-blocker or ACE or ARB-inhibition medication~* Those with hypertrophic, constrictive, or restrictive cardiomyopathies~* Those unable to lie flat in the PET scanner~* Severe major organ system dysfunction (other than heart failure)~* Significant coronary artery disease by catheterization~* Those unable to give informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Men with heart failure (Type: None): Men with obesity-related heart failure
- Women with heart failure (Type: None): Women with obesity-related heart failure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Achieving Blood Pressure Control Through Enhanced Discharge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Present with uncontrolled blood pressure to the emergency department (\>140/90 for non-diabetics and \>130/80 for diabetics)~* Self-reported history of hypertension~Exclusion Criteria:~* End-stage renal disease~* No history of hypertension~* Do not present with uncontrolled blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Enhanced discharge (Type: EXPERIMENTAL): Patient education about hypertension delivered through a touch-screen kiosk at 4 time points in addition to standard discharge.
- Standard discharge (Type: NO_INTERVENTION): Standard discharge is patient instruction, instructions for follow-up to primary care and medication/prescription

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 30 to 80 years Reversible ischemia on a stress SPECT Angina pectoris CCS class \>_ 2 Reduced exercise time \< 10 min No further revascularization options~Exclusion Criteria:~* Pregnant Present or history of cancer Proliferative retinopathy Systemic severe disease LVEF \< 25 % NYHA \> II

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stromal cell (Type: ACTIVE_COMPARATOR): Mesenchymal stromal cell

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone for the Prevention of Postoperative Cognitive Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients over 60 years,~* underwent surgery for inguinal hernia repair, Nissen procedure, cholecystectomy or other surgeries midsize under general anesthesia and hospital stay expected within 72 hours.~Exclusion Criteria:~* age less than 60 years,~* history of brain disease or dementia, other psychiatric disorders that affect cognition,~* lack of proficiency in Portuguese,~* use of corticosteroids or opioid preoperatively.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone, POCD, psycological tests (Type: EXPERIMENTAL): Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery.
- Control, POCD, psycological tests (Type: SHAM_COMPARATOR): Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth.

Study Design Characteristics:
- Allocation: None
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Systemically healthy adults.~* Minimum of 24 permanent teeth.~* No gingivitis (Community Periodontal Index score = 0).~* No periodontitis (Community Periodontal Index score = 0).~* Absence of untreated caries.~Exclusion Criteria:~* Smoker or former smoker.~* Presence of dental prostheses.~* Presence of orthodontic devices.~* Antibiotic treatment or routine use of oral antiseptics in the previous 3 months.~* Presence of any systemic disease that could alter the production or composition of saliva.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Essential oils/0.2% chlorhexidine/Sterile water (Type: EXPERIMENTAL): A) 20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1). -----14 days----- B) 10 mL rinses for 30 seconds with 0.2% chlorhexidine/2 times daily (1/0/1). -----14 days----- C) 20 mL rinses for 30 seconds with sterile water (1/0/1).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of varicella or residence int he US for 30 years~* For Arms C and D - prior live zoster vaccine at least 5 years previously~* For Arms A and B - Age 50-59 or 70-85~* For Arms C and D - Age 70-85~* For women of childbearing potential, a negative pregnancy test and agreement to use adequate contraception from 30 days before until 3 months after the last dose of any study vaccine~Exclusion Criteria:~* History of herpes zoster~* For Arms A and B - prior live zoster vaccine~* Immune compromising illness or therapies or chronic illness~* Allergy to previous herpes zoster vaccine~* Other investigational drugs or vaccines within the past 6 months before the study and until last visit~* Blood products for 3 months prior to or planned during the study~* Concomitant non-topical antiviral therapy within 3 days prior to and 7 days after vaccination.~* Vaccines within 2 weeks (inactive vaccine) or 4 weeks (live vaccine) prior to the study until 30 days after any dose of either vaccine.~* Pregnancy or breast-feeding~* Current drug addiction or alcoholism.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- A - Live zoster vaccine (Type: ACTIVE_COMPARATOR): No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)
- B - recombinant zoster vaccine (Type: ACTIVE_COMPARATOR): No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)
- C - Live zoster vaccine (Type: ACTIVE_COMPARATOR): One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)
- D - recombinant zoster vaccine (Type: ACTIVE_COMPARATOR): One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete